Clinical Scorecard: The Role of Estrogen Levels in Modulating the Gut Microbiome: A Comprehensive Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Hypoestrogenism in women (post-menopausal or premature ovarian insufficiency)
Key Mechanisms
Bidirectional interactions between estrogens and gut microbiome via the estrobolome affecting estrogen metabolism and gut environment
Target Population
Hypoestrogenic women (post-menopausal or POI) compared to euestrogenic pre-menopausal controls
Care Setting
Research and clinical settings focusing on women's reproductive aging and gut microbiome studies
Key Highlights
Meta-analysis of 7 studies including 45 POI, 1222 post-menopausal, and 463 pre-menopausal women showed no significant differences in gut microbiome α-diversity or major bacterial phyla between hypoestrogenic and euestrogenic groups.
High heterogeneity (I² 61-99%) and methodological variability limit the interpretation of current evidence.
The estrobolome mediates gut estrogen metabolism and may influence estrogen availability, but consistent microbiome alterations in hypoestrogenic states remain unproven.
Guideline-Based Recommendations
Diagnosis
Define hypoestrogenic status based on menopausal status or premature ovarian insufficiency criteria.
Exclude confounding factors such as hormonal replacement therapy, active infections, intestinal diseases, or cancer history when studying gut microbiome.
Management
No current evidence supports microbiome-targeted interventions specifically for hypoestrogenic women based on gut microbiome alterations.
Consider comprehensive assessment of confounders (e.g., obesity, diabetes, antibiotics, probiotics, smoking) in clinical evaluation.
Monitoring & Follow-up
Monitor gut microbiome diversity and composition cautiously as current data do not show consistent changes related to estrogen status.
Future monitoring should incorporate standardized sequencing and analytic methods to reduce heterogeneity.
Risks
Interpret findings with caution due to high study heterogeneity and potential confounding factors.
Avoid overgeneralization of gut microbiome alterations in hypoestrogenic women until higher-quality evidence is available.
Patient & Prescribing Data
Women with hypoestrogenism due to menopause or premature ovarian insufficiency
No specific gut microbiome-based treatments are currently supported; hormonal replacement therapy and other interventions should consider individual patient context and existing guidelines.
Clinical Best Practices
Use well-defined criteria for hypoestrogenism and control groups in research and clinical assessments.
Control for confounding factors known to affect gut microbiome composition in study designs and clinical evaluations.
Interpret gut microbiome data in hypoestrogenic women with caution due to inconsistent evidence and methodological variability.
Encourage high-quality, well-controlled studies to clarify the relationship between estrogen status and gut microbiome.
A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.
